# Junta clínica — PT-pseudo_48fb60dfd22f (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_48fb60dfd22f",
  "pid": "PT-pseudo_48fb60dfd22f",
  "task": 1,
  "psa": 24.0,
  "age": 68,
  "months": 1,
  "pirads": "5",
  "psad": 0.986,
  "psav": 3.9,
  "psap": 16.9,
  "vol": 24.35,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.8596296,
  "medhx": "Hypertension, Osteoarthritis",
  "meds": "metoprolol, paracetamol PRN",
  "notes": "PSA 24 ng/mL. PI-RADS 5. PSAD 0.99. Prostate volume 24 mL. csPCa 0.86.",
  "pmhx": [
    "Hypertension",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "189 cm",
    "bmi": "26.0",
    "bp": "130/73 mmHg",
    "hr": "68 bpm",
    "smoking": "Non-smoker",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "14 Feb 2025",
  "enc_ref": "Dr. T. Hendriks (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical reassessment sought after mpMRI acquisition and a PSA increase reaching 24.0 ng/mL."
    },
    {
      "s": "History",
      "t": "A 68-year-old mechanical engineer initiated evaluation in September 2022 due to an elevated PSA reading. He is a non-smoker, and his prior biopsy bucket remains None. Long-standing hypertension is managed with metoprolol, while osteoarthritis discomfort is addressed with paracetamol taken only when necessary. He shares a home with his wife, and adult offspring stop by every week, with their son handling administrative correspondence. Moderate lower urinary tract symptoms produce an IPSS total of 12. A stable cardiology assessment occurred during autumn 2024, accompanied by routine thyroid and vascular checks. Joint stiffness limits his mobility, necessitating a walking frame for extended distances and a ground-floor consultation room. He explicitly denies unexplained weight loss, osseous pain, or nocturnal diaphoresis."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: symmetrically smooth; mobility: unrestricted; asymmetry: absent. The glandular surface presents without palpable nodules, aligning with a normal digital examination. General inspection notes a well-nourished individual in no acute distress, registering a BMI of 26.0. Hemodynamic parameters remain stable at 130/73 mmHg with a regular pulse of 68 bpm. Cardiovascular and respiratory auscultation yield unremarkable results."
    }
  ],
  "occupation": "mechanical engineer",
  "marital": "Married",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Endocrine — thyroid screening",
    "Vascular surgery — varicose veins consult",
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "18 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 12/35 (moderate LUTS)",
  "admin": "Mobility limitation (frame); ground-floor consult room preferred.",
  "mri_hospital": "Tergooi MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_48fb60dfd22f
Task: 1

Encounter: Urology - outpatient on 14 Feb 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 24.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.986 ng/mL²
  - PSA velocity: 3.9 ng/mL/yr
  - Prior PSA: 16.9 ng/mL
  - Prostate volume: 24.35 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8596296 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Osteoarthritis
  - Problem list / PMHx: Hypertension, Osteoarthritis
  - Current medication: metoprolol, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 24 ng/mL. PI-RADS 5. PSAD 0.99. Prostate volume 24 mL. csPCa 0.86.

Vitals: weight 93 kg, height 189 cm, BMI 26.0, BP 130/73 mmHg, HR 68 bpm. Smoking: Non-smoker.

Chief complaint: Clinical reassessment sought after mpMRI acquisition and a PSA increase reaching 24.0 ng/mL.

History: A 68-year-old mechanical engineer initiated evaluation in September 2022 due to an elevated PSA reading. He is a non-smoker, and his prior biopsy bucket remains None. Long-standing hypertension is managed with metoprolol, while osteoarthritis discomfort is addressed with paracetamol taken only when necessary. He shares a home with his wife, and adult offspring stop by every week, with their son handling administrative correspondence. Moderate lower urinary tract symptoms produce an IPSS total of 12. A stable cardiology assessment occurred during autumn 2024, accompanied by routine thyroid and vascular checks. Joint stiffness limits his mobility, necessitating a walking frame for extended distances and a ground-floor consultation room. He explicitly denies unexplained weight loss, osseous pain, or nocturnal diaphoresis.

Physical examination: DRE — texture: symmetrically smooth; mobility: unrestricted; asymmetry: absent. The glandular surface presents without palpable nodules, aligning with a normal digital examination. General inspection notes a well-nourished individual in no acute distress, registering a BMI of 26.0. Hemodynamic parameters remain stable at 130/73 mmHg with a regular pulse of 68 bpm. Cardiovascular and respiratory auscultation yield unremarkable results.

Patient info: mechanical engineer; Married; Lives with partner; adult children visit weekly.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 18 units / week; exercise Running 3x/week, 5 km; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Endocrine — thyroid screening; Vascular surgery — varicose veins consult; Cardiology — annual review (stable, autumn 2024).
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.83
  uncertainty  +/- 0.09 epistemic (95% band 0.66-1.00); among patients I cannot tell apart the outcome was 0.66 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 24.0, PSAD 0.986, age 68, DRE Normal -> BIOPSY (clear). He wrote: "PIRADS 5 needs biopsy"
  2. distance 0.47: PI-RADS 5, PSA 22.0, PSAD 0.696, age 68, DRE Normal -> BIOPSY (clear). He wrote: "Biopsy-naive PIRADS 5 needs biopsy"
  3. distance 0.51: PI-RADS 5, PSA 16.8, PSAD 0.846, age 69, DRE Normal -> BIOPSY (clear). He wrote: "PIRADS 5 needs biopsy"

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: fh=noted, pirads=decisive, dre=noted, psa=decisive, comorbidity=noted, cspca=important, vol=important, age=important, psad=decisive, bx=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines link PI-RADS scores to the indication for biopsy, stating that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy. The guideline also notes that MRI-directed US-guided prostate biopsy is now the standard of care.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled by the guideline because the guideline does not account for the patient's specific clinical context, such as the prior biopsy status or the specific PSA density value. Expert 4's focus on the PI-RADS score is insufficient because the guideline suggests that the decision must be made in the context of the overall risk profile, which is not fully captured by the PI-RADS score alone.

WHAT WE STILL NEED
The guideline requires establishing the PSA density value to determine if it falls into the risk-adapted matrix. The panel shows the PSA density is $0.986 \text{ ng/mL}^2$. This value is crucial because the guideline references PSA-D cut-offs (e.g., $0.15 \text{ ng/mL/cc}$) in relation to the PI-RADS score. The panel shows the prior biopsy status is "None," which is a factor the guideline considers in risk stratification.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PSA density value dictates the next step according to the EAU guidelines, given the PI-RADS 5 and no prior biopsy.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the PI-RADS 5 lesion?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values?
  previous_notes (get_previous_notes) -> What is the management context regarding prior biopsy status, surveillance protocol, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. Given the PI-RADS 5 and no prior biopsy, what is the required management pathway according to the cohort criterion?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "What is the implication of the PSA density value of $0.986 ext{ ng/mL}^2$ in relation to the EAU guidelines for biopsy indication?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone of the PI-RADS 5 lesion is: "A discrete focus occupies the right peripheral zone at the mid-gland posterior aspect, spanning 14 x 11 x 10 mm."
psa_trend
The trend of the serial PSA values is: [{"date": "Sep 2022", "val": 11.8}, {"date": "Dec 2023", "val": 9.8}, {"date": "Feb 2025", "val": 24.0}].
previous_notes
The management context regarding prior biopsy status, surveillance protocol, and planned treatment is: "Prior biopsy: None. Surveillance protocol: not recorded. Planned treatment: not recorded."

WHAT I DID NOT OPEN
I did not open the laboratory_results because the panel data was already summarized in the initial prompt.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 lesion located in the right mid-peripheral zone.
PSA trend shows a significant increase from 9.8 ng/mL in Dec 2023 to 24.0 ng/mL in Feb 2025.

Findings that argue AGAINST sampling this patient now:
Prior biopsy status is "None".

WHERE THIS LEANS
The findings strongly support a biopsy due to the PI-RADS 5 score and the rising PSA trend, which aligns with the cohort criterion.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (clear). Last value 24.00 ng/mL over 3 points spanning 29 months; velocity +4.97 ng/mL per year; doubling time about 29 months.
PROJECTION at 6 months: 89.0 ng/mL, conformal 95% band 25.5-310.4.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.81
  uncertainty  +/- 0.07 epistemic (95% band 0.67-0.95), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.83  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.81  ('firm' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (identical panel in the series)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: fh=noted, pirads=decisive, dre=noted, psa=decisive, comorbidity=noted, cspca=important, vol=important, age=important, psad=decisive, bx=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, and previous_notes—directly address the core elements of the open questions. The radiology report provided lesion size and zone, the PSA trend showed a significant rise, and the previous notes confirmed the prior biopsy status was "None."

ALIGNMENT WITH THE PANEL
The retrieved evidence strongly aligns with the PANEL-PROTOCOL's answer of BIOPSY. Specifically, the PI-RADS 5 score and the rising PSA trend support the cohort criterion, and the previous notes confirm the lack of prior biopsy, which is a factor weighted by the trace model.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Given the PI-RADS 5 and no prior biopsy, what is the required management pathway according to the cohort criterion? This question is answered by the EXPERT-COHORT, which states the criterion is to sample when the mpMRI shows a PI-RADS 3 or higher lesion, leading to a recommendation for BIOPSY.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 5 score is the most critical variable as it is decisive for the cohort criterion. The rising PSA trend is also highly relevant as it indicates disease activity, supporting the need for intervention. The lack of prior biopsy is also a key factor in the risk stratification.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy based on the alignment between the cohort criterion and the retrieved findings. The evidence supports a firm recommendation for biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended based on the convergence of evidence, driven primarily by the PI-RADS 5 score and the rising PSA trend. The cohort criterion supports sampling when PI-RADS is 3 or higher, and the lack of prior biopsy further supports intervention. The evidence converged because the retrieved findings, specifically the PI-RADS 5 score and the rising PSA trend, strongly supported the need for a biopsy.

What carried weight: pirads=decisive, psa=decisive, comorbidity=noted, cspca=important, vol=important, age=important, psad=decisive, bx=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
